1-3 of 3
Andres Wiernik
Close
Sort by
Journal Articles

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33 + targets

Michelle K. Gleason, Julie A. Ross, Erica D. Warlick, Troy C. Lund, Michael R. Verneris, Andres Wiernik, Stephen Spellman, Michael D. Haagenson, Alexander J. Lenvik, Mark R. Litzow, Pearlie K. Epling-Burnette, Bruce R. Blazar, Louis M. Weiner, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller
Journal: Blood
Blood (2014) 123 (19): 3016–3026.
https://doi.org/10.1182/blood-2013-10-533398
Published: 2014
Includes: Supplemental data
Journal Articles

A Novel CD16xCD33 Bispecific Killer Cell Engager (BiKE) Mediates a Double Hit For Natural Killer (NK) Cells To Target CD33 + Myelodysplastic Syndrome (MDS) Cells and Myeloid Derived Suppressor Cells (MDSCs) At All Disease Stages

Michelle K. Gleason, PhD, Julie A. Ross, PhD, Troy C. Lund, MD/PhD, Michael R. Verneris, MD, Andres Wiernik, MD, Erica D. Warlick, MD, Stephen Spellman, MBS, Michael D. Haagenson, MS, Alexander J. Lenvik, Mark R. Litzow, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2013) 122 (21): 385.
https://doi.org/10.1182/blood.V122.21.385.385
Published: 2013
Journal Articles

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Andres Wiernik, MD, Bree Foley, PhD, Bin Zhang, Michael R. Verneris, MD, Erica Warlick, MD, Julie A. Ross, PhD, Louis M. Weiner, MD, Daniel J. Weisdorf, MD, Daniel A Vallera, PhD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2012) 120 (21): 256.
https://doi.org/10.1182/blood.V120.21.256.256
Published: 2012